Loading...
NEJM Group was on hand to cover the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, held January 23 to 25 in San Francisco. Here, NEJM Journal Watch Oncology and Hematology Associate Editor Dr. David Ilson reviews key trials. Abstracts are available in the meeting proceedings.
In patients with unresectable or metastatic colorectal cancer and microsatellite instability–high or mismatch repair–deficient (MSI-H/dMMR) status, treatment with nivolumab plus ipilimumab improves progression-free survival (PFS) compared with nivolumab alone, according to findings from the industry-supported, phase 3, open-la…